Table 1 Ongoing clinical evaluations of ruxolitinib in combination with other compounds for treatment of MPNs
Compounds | Target/mechanism | National Clinical Trial Identifier | Phase | Condition | Status |
|---|---|---|---|---|---|
Decitabine | Anti-metabolite chemotherapeutic, DNA demethylation | NCT02076191 | I/II | Accelerated or blast phase MPN | Recruiting |
Azacitidine (Vidaza) | Chemical analogue of nucleoside cytidine, antimetabloite chemotherapeutic | NCT01787487 | III | MF, MDS/MPN | Recruiting |
NCT02257138 | I/II | AML, post MPN-AML | Active, not recruiting | ||
Danazol | Synthetic steroid derived from ethisterone, used in endometriosis treatment | NCT01732445 | II | Anemia in PMF, post ET/ PV MF | Recruitment suspended for interim data to mature |
Pracinostat (SB939) | Hydroxamic acid based histone deacetylatase inhibitor of class 1/2/4 HDACs | NCT02267278 | II | MF | Active, not recruiting |
Panobinostat (LBH589) | Hydroxamic acid based non selective HDAC inhibitor | NCT01693601 | I/II | MF | Recruiting |
NCT01433445 | I | PMF, post ET/ PV MF | Active, not recruiting | ||
Pomalidomide (CC-4047-MM-002) | Derivative of thalidomide, inhibits angiogenesis, immunomodulator | NCT01644110 | I/II | PMF, post ET/PV MF | Recruiting |
Lenalidomide | Anti-angiogenic, immunomodulator | NCT01375140 | II | MF | Active, not recruiting |
Simtuzumab (GS-6624) | Humanized monoclonal antibody, binds to LOXL2 and inhibits fibrosis | NCT01369498 | II | PMF, post ET/PV MF | Completed |
PRM-151 | Recombinant pentraxin-2 protein (acute immunological responses) inhibits fibrosis | NCT01981850 | II | PMF, post ET/PV MF | Recruiting |
BKM120 | PI3K inhibitor | NCT01730248 | I | PMF, post ET/PV MF | Recruiting |
LDE225 | Investigational inhibitor of Smoothened (SMO), a regulator of hedgehog signaling pathway | NCT01787552 | Ib/II | PMF, ET, MPD | Recruiting |